Takeda Pharmaceutical Co. Ltd. Sponsored ADR(TAK.US) The two key Phase III studies of TAK-861 for the treatment of type 1 narcolepsy have achieved positive results.

On July 14th, Takeda Pharmaceutical Co. Ltd. Sponsored ADR (TAK.US) announced that the two Phase III randomized, double-blind, placebo-controlled studies for Oveporexton (TAK-861) in type 1 narcolepsy (NT1) have met all major and secondary endpoints. Oveporexton (TAK-861) is a potential first-in-class oral selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1. NT1 is caused by the loss of orexin-producing neurons in the brain, and orexin agonists are designed to address this underlying orexin deficiency. This mechanism of action was validated for the first time in Phase III studies, significantly improving a range of clinical symptoms of the disease, further demonstrating the potential of Oveporexton in changing the standard treatment of NT1. Christophe Weber, President and CEO of Takeda Pharmaceutical Co. Ltd. Sponsored ADR, stated, "We are pleased to have achieved this key milestone in the development of Oveporexton, demonstrating Takeda's research capabilities in difficult-to-treat diseases such as NT1. Takeda holds a pioneering position in the orexin life sciences field, and through a diverse pipeline of orexin products, we are driving significant changes in this field, ensuring long-term steady growth of the company's future business."